Nuvalent (NUVL) Competitors $77.00 +0.25 (+0.33%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVL vs. SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, and ROIVShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Nuvalent vs. Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Summit Therapeutics (NASDAQ:SMMT) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate SMMT or NUVL? Summit Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 52.32%. Nuvalent has a consensus price target of $115.50, indicating a potential upside of 50.50%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvalent 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Do institutionals & insiders hold more shares of SMMT or NUVL? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by company insiders. Comparatively, 12.5% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in SMMT or NUVL? Summit Therapeutics received 266 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.95% of users gave Nuvalent an outperform vote while only 58.57% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes31158.57% Underperform Votes22041.43% NuvalentOutperform Votes4578.95% Underperform Votes1221.05% Which has more risk & volatility, SMMT or NUVL? Summit Therapeutics has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Which has higher earnings & valuation, SMMT or NUVL? Nuvalent has lower revenue, but higher earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K25,944.21-$614.93M-$0.31-79.42NuvalentN/AN/A-$126.22M-$3.90-19.68 Is SMMT or NUVL more profitable? Nuvalent's return on equity of -28.63% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Nuvalent N/A -28.63%-27.15% Does the media refer more to SMMT or NUVL? In the previous week, Summit Therapeutics had 11 more articles in the media than Nuvalent. MarketBeat recorded 25 mentions for Summit Therapeutics and 14 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.04 beat Summit Therapeutics' score of 0.71 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryNuvalent beats Summit Therapeutics on 9 of the 17 factors compared between the two stocks. Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.49B$6.79B$5.53B$7.99BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-22.087.4422.6518.64Price / SalesN/A244.75401.98103.80Price / CashN/A65.8538.1834.62Price / Book7.026.536.754.30Net Income-$126.22M$143.43M$3.22B$248.44M7 Day Performance3.74%2.23%1.66%1.81%1 Month Performance12.86%7.19%4.17%4.40%1 Year Performance8.63%-2.24%16.17%5.97% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent1.8879 of 5 stars$77.00+0.3%$115.50+50.0%+11.4%$5.51BN/A-22.1740Upcoming EarningsPositive NewsSMMTSummit Therapeutics2.6798 of 5 stars$25.22+2.5%$35.40+40.4%+513.7%$18.60B$700,000.00-90.07110Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries3.2702 of 5 stars$13.30-2.6%$23.43+76.2%+10.5%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst UpgradeAnalyst RevisionPositive NewsGap UpITCIIntra-Cellular Therapies0.8793 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4448 of 5 stars$20.07+0.1%$39.17+95.2%-23.6%$13.28B$21.53B11.531,660Upcoming EarningsAnalyst RevisionPositive NewsRDYDr. Reddy's Laboratories1.8486 of 5 stars$13.68+0.1%$17.00+24.3%-5.3%$11.42B$311.31B21.7824,800Upcoming EarningsPositive NewsASNDAscendis Pharma A/S2.3116 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Positive NewsMRNAModerna4.4322 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.8326 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6936 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.2052 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860Positive News Related Companies and Tools Related Companies SMMT Competitors TEVA Competitors ITCI Competitors GMAB Competitors RDY Competitors ASND Competitors MRNA Competitors VTRS Competitors QGEN Competitors ROIV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NUVL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
